Pertussis: Relevant species and diagnostic update

Clinics in Laboratory Medicine

Volumn 34, Issue 2, 2014, Pages 237-255

  Leber, Amy L ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Bordetella epidemiology; Bordetella holmesii infection; Bordetella parapertussis infection; Bordetella pertussis PCR; Pertussis laboratory diagnosis; Pertussis serology

Indexed keywords

ACELLULAR VACCINE; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; MACROLIDE; PERTUSSIS VACCINE;

AGE DISTRIBUTION; AWARENESS; BACTERIUM CULTURE; BORDETELLA HOLMESII; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; DIAGNOSTIC TEST; DRUG EFFICACY; HUMAN; LABORATORY DIAGNOSIS; MOLECULAR DIAGNOSIS; NUCLEIC ACID AMPLIFICATION; PERTUSSIS; PHYSICIAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEROLOGY; SPECIES DIFFERENTIATION; ADOLESCENT; ADULT; CHILD; EPIDEMIC; INCIDENCE; INFANT; MICROBIOLOGY; MOLECULAR TYPING; NEWBORN; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; UNITED STATES; WHOOPING COUGH; YOUNG ADULT;

ADOLESCENT; ADULT; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MOLECULAR TYPING; POLYMERASE CHAIN REACTION; UNITED STATES; WHOOPING COUGH; YOUNG ADULT;

EID: 84901274026     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2014.02.003     Document Type: Review

References (100)

1. Loeffelholz M.J., Sanden G.N. Manual of clinical microbiology 2007, vol. 1. ASM Press, Washington, DC.
2. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005, 18:326-382.
3. Leber A., Salamon D., Prince P. Pertussis diagnosis in the 21st century: progress and pitfalls, part 1. Clin Microbiol Newsl 2011, 33:111-115.
4. Leber A., Salamon D., Prince P. Pertussis diagnosis in the 21st century: progress and pitfalls, part II. Clin Microbiol Newsl 2011, 33:119-126.
5. Clinical and Laboratory Standards Institute. Interpretive criteria for identification of bacteria and fungi by DNA target sequencing; approved guideline, MM18-A. 2008; 28. Available at:. http://www.clsi.org/standards/.
6. McGowan K. Bordetella cultures. Clinical microbiology procedures handbook 2007, vol. 1:1-14. ASM Press, Washington, DC. 3rd edition.
7. Guris D., Strebel P.M., Bardenheier B., et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999, 28:1230-1237.
8. Centers for Disease Control and Prevention. Notes from the field: pertussis-California,January-June 2010. Available at:. Accessed November 13, 2010. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5926a5.htm?s_cid=mm5926a5_e%0d%0a.
9. Litt D.J., Neal S.E., Fry N.K. Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type. JClin Microbiol 2009, 47:680-688.
10. Cherry J.D. Epidemiology of pertussis. Pediatr Infect Dis J 2006, 25:361-362.
11. Bouchez V., Brun D., Cantinelli T., et al. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 2009, 27:6034-6041.
12. Pawloski L.C., Queenan A.M., Cassiday P.K., et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the US. Clin Vaccine Immunol 2014, 21(2):119-125.
13. Cherry J.D., Seaton B.L. Patterns of Bordetella parapertussis respiratory illnesses: 2008-2010. Clin Infect Dis 2012, 54:534-537.
14. Wallihan R., Selvarangan R., Marcon M., et al. Bordetella parapertussis bacteremia: two case reports. Pediatr Infect Dis J 2013, 32:796-798.
15. Njamkepo E., Delisle F., Hagege I., et al. Bordetella holmesii isolated from a patient with sickle cell anemia: analysis and comparison with other Bordetella holmesii isolates. Clin Microbiol Infect 2000, 6:131-136.
16. Weyant R.S., Hollis D.G., Weaver R.E., et al. Bordetella holmesii sp. nov., a new gram-negative species associated with septicemia. JClin Microbiol 1995, 33:1-7.
17. Yih W.K., Silva E.A., Ida J., et al. Bordetella holmesii-like organisms isolated from Massachusetts patients with pertussis-like symptoms. Emerg Infect Dis 1999, 5:441-443.
18. Mazengia E., Silva E.A., Peppe J.A., et al. Recovery of Bordetella holmesii from patients with pertussis-like symptoms: use of pulsed-field gel electrophoresis to characterize circulating strains. JClin Microbiol 2000, 38:2330-2333.
19. Antila M., He Q., de Jong C., et al. Bordetella holmesii DNA is not detected in nasopharyngeal swabs from Finnish and Dutch patients with suspected pertussis. JMed Microbiol 2006, 55:1043-1051.
20. Riffelmann M., Wirsing von Konig C.H., Caro V., et al. Nucleic acid amplification tests for diagnosis of Bordetella infections. JClin Microbiol 2005, 43:4925-4929.
21. Rodgers L., Martin S.W., Cohn A., et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis-Ohio, 2010-2011. Clin Infect Dis 2013, 56:322-331.
22. Spicer KB, Salamon D, Cummins C, etal. Occurrence of three Bordetella species during an outbreak of cough illness in Ohio: epidemiology, clinical features, laboratory findings, and antimicrobial susceptibility. Pediatr Infect Dis J 2014 Jan 17. [Epub ahead of print].
23. Njamkepo E., Bonacorsi S., Debruyne M., et al. Significant finding of Bordetella holmesii DNA in nasopharyngeal samples from French patients with suspected pertussis. JClin Microbiol 2011, 49:4347-4348.
24. Kamiya H., Otsuka N., Ando Y., et al. Transmission of Bordetella holmesii during pertussis outbreak, Japan. Emerg Infect Dis 2012, 18:1166-1169.
25. Tatti K.M., Wu K.H., Tondella M.L., et al. Development and evaluation of dual-target real-time polymerase chain reaction assays to detect Bordetella spp. Diagn Microbiol Infect Dis 2008, 61:264-272.
26. Heininger U., Stehr K., Schmitt-Grohe S., et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J 1994, 13:306-309.
27. Long S.S., Welkon C.J., Clark J.L. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. JInfect Dis 1990, 161:480-486.
28. Mink C.M., Cherry J.D., Christenson P., et al. Asearch for Bordetella pertussis infection in university students. Clin Infect Dis 1992, 14:464-471.
29. Hallander H.O., Ljungman M., Storsaeter J., et al. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. APMIS 2009, 117:797-807.
30. Le T., Cherry J.D., Chang S.J., et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. JInfect Dis 2004, 190:535-544.
31. Heininger U., Cherry J.D., Stehr K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis 2004, 38:591-594.
32. Forsyth K.D., Campins-Marti M., Caro J., et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004, 39:1802-1809.
33. Edelman K., He Q., Makinen J., et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007, 44:1271-1277.
34. Sin M.A., Zenke R., Ronckendorf R., et al. Pertussis outbreak in primary and secondary schools in Ludwigslust, Germany demonstrating the role of waning immunity. Pediatr Infect Dis J 2009, 28:242-244.
35. Broder K.R., Cortese M.M., Iskander J.K., et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1-34.
36. Kretsinger K., Broder K.R., Cortese M.M., et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006, 55:1-37.
37. Klein N.P., Bartlett J., Rowhani-Rahbar A., et al. Waning protection after fifth dose of acellular pertussis vaccine in children. NEngl J Med 2012, 367:1012-1019.
38. Centers for Disease Control and Prevention Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Recomm Rep 2011, 60:1424-1426.
39. Centers for Disease Control and Prevention Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women-Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Recomm Rep 2013, 62:131-135.
40. Halperin B.A., Morris A., Mackinnon-Cameron D., et al. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis 2011, 53:885-892.
41. Mooi F.R., de Greeff S.C. The case for maternal vaccination against pertussis. Lancet Infect Dis 2007, 7:614-624.
42. Wei S.C., Tatti K., Cushing K., et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis 2010, 51:315-321.
43. Kallonen T., He Q. Bordetella pertussis strain variation and evolution postvaccination. Expert Review Vaccines 2009, 8:863-875.
44. Queenan A.M., Cassiday P.K., Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. NEngl J Med 2013, 368:583-584.
45. Cornia P.B., Hersh A.L., Lipsky B.A., et al. Does this coughing adolescent or adult patient have pertussis?. JAMA 2010, 304:890-896.
46. van der Zee A., Agterberg C., Peeters M., et al. Aclinical validation of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population. JInfect Dis 1996, 174:89-96.
47. Centers for Disease Control and Prevention. Pertussis (Bordetella pertussis) (whooping cough) 2010 Case Definition CSTE Position Statement Number: 09-ID-51. Available at:. Accessed November 18, 2010. http://www.cdc.gov/ncphi/disss/nndss/print/pertussis_current.htm.
48. World Health Organization. WHO-recommended standards for surveillance of selected vaccine-preventable diseases. 2003; WHO/V&B/03.01. Available at:. http://whqlibdoc.who.int/hq/2003/who_v%26b_03.01.pdf.
49. Cherry J.D., Tan T., Wirsing von Konig C.H., et al. Clinical definitions of pertussis: summary of a Global Pertussis Initiative roundtable meeting, February 2011. Clin Infect Dis 2012, 54:1756-1764.
50. Farrell D.J., Daggard G., Mukkur T.K. Nested duplex PCR to detect Bordetella pertussis and Bordetella parapertussis and its application in diagnosis of pertussis in nonmetropolitan Southeast Queensland, Australia. JClin Microbiol 1999, 37:606-610.
51. Cloud J.L., Hymas W., Carroll K.C. Impact of nasopharyngeal swab types on detection of Bordetella pertussis by PCR and culture. JClin Microbiol 2002, 40:3838-3840.
52. Wadowsky R.M., Laus S., Libert T., et al. Inhibition of PCR-based assay for Bordetella pertussis by using calcium alginate fiber and aluminum shaft components of a nasopharyngeal swab. JClin Microbiol 1994, 32:1054-1057.
53. Muller F.M., Hoppe J.E., Wirsing von Konig C.H. Laboratory diagnosis of pertussis: state of the art in 1997. JClin Microbiol 1997, 35:2435-2443.
54. Sotir M.J., Cappozzo D.L., Warshauer D.M., et al. Evaluation of polymerase chain reaction and culture for diagnosis of pertussis in the control of a county-wide outbreak focused among adolescents and adults. Clin Infect Dis 2007, 44:1216-1219.
55. Houard S., Hackel C., Herzog A., et al. Specific identification of Bordetella pertussis by the polymerase chain reaction. Res Microbiol 1989, 140:477-487.
56. Douglas E., Coote J.G., Parton R., et al. Identification of Bordetella pertussis in nasopharyngeal swabs by PCR amplification of a region of the adenylate cyclase gene. JMed Microbiol 1993, 38:140-144.
57. Vincart B., De Mendonca R., Rottiers S., et al. Aspecific real-time PCR assay for the detection of Bordetella pertussis. JMed Microbiol 2007, 56:918-920.
58. Wendelboe A.M., Van Rie A. Diagnosis of pertussis: a historical review and recent developments. Expert Rev Mol Diagn 2006, 6:857-864.
59. Glare E.M., Paton J.C., Premier R.R., et al. Analysis of a repetitive DNA sequence from Bordetella pertussis and its application to the diagnosis of pertussis using the polymerase chain reaction. JClin Microbiol 1990, 28:1982-1987.
60. van der Zee A., Agterberg C., van Agterveld M., et al. Characterization of IS1001, an insertion sequence element of Bordetella parapertussis. JBacteriol 1993, 175:141-147.
61. Templeton K.E., Scheltinga S.A., van der Zee A., et al. Evaluation of real-time PCR for detection of and discrimination between Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii for clinical diagnosis. JClin Microbiol 2003, 41:4121-4126.
62. Sloan L.M., Hopkins M.K., Mitchell P.S., et al. Multiplex LightCycler PCR assay for detection and differentiation of Bordetella pertussis and Bordetella parapertussis in nasopharyngeal specimens. JClin Microbiol 2002, 40:96-100.
63. Nakamura Y., Kamachi K., Toyoizumi-Ajisaka H., et al. Marked difference between adults and children in Bordetella pertussis DNA load in nasopharyngeal swabs. Clin Microbiol Infect 2010, 17(3):365-370.
64. Register K.B., Nicholson T.L. Misidentification of Bordetella bronchiseptica as Bordetella pertussis using a newly described real-time PCR targeting the pertactin gene. JMed Microbiol 2007, 56:1608-1610.
65. Register K.B., Nicholson T.L., Guthrie J.L. Evaluation of specificity of BP3385 for Bordetella pertussis detection. JClin Microbiol 2010, 48:3334-3337.
66. Parkhill J., Sebaihia M., Preston A., et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 2003, 35:32-40.
67. Loeffelholz M.J., Thompson C.J., Long K.S., et al. Comparison of PCR, culture, and direct fluorescent-antibody testing for detection of Bordetella pertussis. JClin Microbiol 1999, 37:2872-2876.
68. Koidl C., Bozic M., Burmeister A., et al. Detection and differentiation of Bordetella spp. by real-time PCR. JClin Microbiol 2007, 45:347-350.
69. Diavatopoulos D.A., Cummings C.A., Schouls L.M., et al. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog 2005, 1:e45.
70. Register K.B., Sanden G.N. Prevalence and sequence variants of IS481 in Bordetella bronchiseptica: implications for IS481-based detection of Bordetella pertussis. JClin Microbiol 2006, 44:4577-4583.
71. Reischl U., Lehn N., Sanden G.N., et al. Real-time PCR assay targeting IS481 of Bordetella pertussis and molecular basis for detecting Bordetella holmesii. JClin Microbiol 2001, 39:1963-1966.
72. Dragsted D.M., Dohn B., Madsen J., et al. Comparison of culture and PCR for detection of Bordetella pertussis and Bordetella parapertussis under routine laboratory conditions. JMed Microbiol 2004, 53:749-754.
73. Xu Y., Hou Q., Yang R., et al. Triplex real-time PCR assay for detection and differentiation of Bordetella pertussis and Bordetella parapertussis. APMIS 2010, 118:685-691.
74. Guthrie J.L., Robertson A.V., Tang P., et al. Novel duplex real-time PCR assay detects Bordetella holmesii in specimens from patients with pertussis-like symptoms in Ontario, Canada. JClin Microbiol 2010, 48:1435-1437.
75. Tatti K.M., Sparks K.N., Boney K.O., et al. Novel multitarget real-time PCR assay for rapid detection of Bordetella species in clinical specimens. JClin Microbiol 2011, 49:4059-4066.
76. Papenburg J., Fontela P. What is the significance of a high cycle threshold positive IS481 PCR for Bordetella pertussis?. Pediatr Infect Dis J 2009, 28:1143. [author reply: 1143-4].
77. Guthrie J.L., Seah C., Brown S., et al. Use of Bordetella pertussis BP3385 to establish a cutoff value for an IS481-targeted real-time PCR assay. JClin Microbiol 2008, 46:3798-3799.
78. Otsuka N., Yoshino S., Kawano K., et al. Simple and specific detection of Bordetella holmesii by using a loop-mediated isothermal amplification assay. Microbiol Immunol 2012, 56:486-489.
79. Kamachi K., Toyoizumi-Ajisaka H., Toda K., et al. Development and evaluation of a loop-mediated isothermal amplification method for rapid diagnosis of Bordetella pertussis infection. JClin Microbiol 2006, 44:1899-1902.
80. Centers for Disease Control and Prevention Outbreaks or respiratory illness mistakenly attributed to pertussis-New Hampshire, Massachusetts, and Tennessee, 2004-2006. MMWR Morb Mortal Wkly Rep 2007, 56:837-842.
81. Taranger J., Trollfors B., Lind L., et al. Environmental contamination leading to false-positive polymerase chain reaction for pertussis. Pediatr Infect Dis J 1994, 13:936-937.
82. Tatti K.M., Slade B., Patel M., et al. Real-time polymerase chain reaction detection of Bordetella pertussis DNA in acellular pertussis vaccines. Pediatr Infect Dis J 2008, 27:73-74.
83. Leber A, Salamon D, Cummins C, etal. Detection of Bordetella pertussis DNA in acellular vaccines and in environmental samples from pediatric physician offices. Abstract number D-149. In: Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Boston (MA).
84. Cherry J.D., Grimprel E., Guiso N., et al. Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J 2005, 24:S25-S34.
85. Isacson J., Trollfors B., Hedvall G., et al. Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. Scand J Infect Dis 1995, 27:273-277.
86. Hallander H.O. Microbiological and serological diagnosis of pertussis. Clin Infect Dis 1999, 28(Suppl 2):S99-S106.
87. Greenberg D.P. Pertussis in adolescents: increasing incidence brings attention to the need for booster immunization of adolescents. Pediatr Infect Dis J 2005, 24:721-728.
88. Ward J.I., Cherry J.D., Chang S.J., et al. Bordetella pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis 2006, 43:151-157.
89. Xing D., Markey K., Newland P., et al. EUVAC.NET collaborative study: evaluation and standardisation of serology for diagnosis of pertussis. JImmunol Methods 2011, 372:137-145.
90. Pawloski L.C., Kirkland K.B., Baughman A.L., et al. Does tetanus-diphtheria-acellular pertussis vaccination interfere with serodiagnosis of pertussis infection?. Clin Vaccine Immunol 2012, 19:875-880.
91. Hoppe J.E. Update of epidemiology, diagnosis, and treatment of pertussis. Eur J Clin Microbiol Infect Dis 1996, 15:189-193.
92. Burstyn D.G., Baraff L.J., Peppler M.S., et al. Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect Immun 1983, 41:1150-1156.
93. Cherry J.D. Pertussis in adults. Ann Intern Med 1998, 128:64-66.
94. Granstrom G., Wretlind B., Salenstedt C.R., et al. Evaluation of serologic assays for diagnosis of whooping cough. JClin Microbiol 1988, 26:1818-1823.
95. Steketee R.W., Burstyn D.G., Wassilak S.G., et al. Acomparison of laboratory and clinical methods for diagnosing pertussis in an outbreak in a facility for the developmentally disabled. JInfect Dis 1988, 157:441-449.
96. Klement E., Kagan N., Hagain L., et al. Correlation of IgA, IgM and IgG antibody-detecting assays based on filamentous haemagglutinin, pertussis toxin and Bordetella pertussis sonicate in a strictly adult population. Epidemiol Infect 2005, 133:149-158.
97. Menzies S.L., Kadwad V., Pawloski L.C., et al. Development and analytical validation of an immunoassay for quantifying serum anti-pertussis toxin antibodies resulting from Bordetella pertussis infection. Clin Vaccine Immunol 2009, 16:1781-1788.
98. Tiwari T., Murphy T.V., Moran J. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005, 54:1-16.
99. Bartkus J.M., Juni B.A., Ehresmann K., et al. Identification of a mutation associated with erythromycin resistance in Bordetella pertussis: implications for surveillance of antimicrobial resistance. JClin Microbiol 2003, 41:1167-1172.
100. Guillot S., Descours G., Gillet Y., et al. Macrolide-resistant Bordetella pertussis infection in newborn girl, France. Emerg Infect Dis 2012, 18:966-968.